| Ytd | -59.38% | |
| 1y | -64.86% |
| Open | 1.74 | Prev Close | 1.72 | Low | 1.64 | High | 1.83 | Mkt Cap | 57.45M |
| Vol | 116.27K | Avg Vol | 70.99K | EPS | 1.89 | P/E | 0.89 | Forward P/E | -0.43 |
| Beta | 1.81 | Short Ratio | 0.42 | Inst. Own | 3.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 1.90 | 200-d Avg | 2.54 | 1yr Est | 13.83 |
DWTX News
- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range - - Topline Data Exp
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's afte
Gainers Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market sess
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced
Dogwood Therapeutics NASDAQ: DWTX said its Phase 2b study of Halneuron, an investigational treatment
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday
ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwo
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.34) per share which missed the a
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fal
Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) shares traded up 4.3% during trading on M
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”)
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in adva
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a biopharmace
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional saf
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.15) per share which met the anal
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fal
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or th
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharm
REGENXBIO (NASDAQ: RGNX - Get Free Report) and Dogwood Therapeutics (NASDAQ: DWTX - Get Free Report)
Dogwood Therapeutics (NASDAQ: DWTX - Get Free Report) is projected to issue its Q4 2025 results befo
ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”
Shares of Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) were up 1.7% during mid-day tra
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halne
Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) was the recipient of a significant increa
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The comp
